Ascendis Pharma A/S

NASDAQ•ASND

CEO: Mr. Jan Moller Mikkelsen

セクター: Healthcare

業種: Biotechnology

上場日: 2015-01-28

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

連絡先情報

Tuborg Boulevard 12, Hellerup, 2900, Denmark

45-70-22-22-44

ascendispharma.com

時価総額

$14.00B

PER (TTM)

-53.3

17.2

配当利回り

52週高値

$248.60

52週安値

$124.06

52週レンジ

84%

順位55Top 80.0%

2.6

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 2.6 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$285.45M+0.00%

直近4四半期の推移

EPS

-$0.63+0.00%

直近4四半期の推移

フリーCF

$78.44M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Revenue Surge Driven by YORVIPATH Total revenue €720.1M, up €356.5M; YORVIPATH sales €477.4M, up €448.7M compared to 2024.

Operating Loss Significantly Reduced Operating loss €136.3M, improvement €142.5M versus prior year's €278.8M loss reported for 2024.

Positive Operating Cash Flow Cash flow from operations €53.9M, a €360.1M improvement from prior period cash usage of €306.2M.

Pipeline Milestones Achieved Secured Novo Nordisk deal; TransCon CNP NDA priority review with FDA PDUFA goal February 28, 2026.

リスク要因

Future Viability Concerns Significant future losses incurred, making future viability assessment difficult; total equity deficit €162.8M.

Financing Dependency Risk Failure to secure needed capital could force delay, limit, or cease commercialization activities and product development.

Product Success Uncertainty Substantial dependence on product candidates succeeding in clinical trials or receiving necessary regulatory approval.

Supply Chain Single Source Reliance on third-parties for manufacturing, including single-source suppliers, risks material adverse business impact.

見通し

Vision 2030 Blockbuster Goal Pursue Vision 2030 goal: achieve >€5B revenue for key products via worldwide commercialization efforts.

Pipeline Expansion Focus Expand pipeline in Endocrinology Rare Disease and pursue TransCon opportunities in >€5B indications.

Global Commercialization Execution Execute integrated organization strategy across US, Europe Direct, and International Markets for product launches.

Technology Platform Leverage Maximize value creation by leveraging TransCon technology platform through strategic collaborations with market leaders.

同業比較

売上高 (TTM)

BAX

$11.24B

+5.7%

BMRN

$3.22B

+12.9%

RPRX

$2.38B

+5.1%

粗利益率 (最新四半期)

RPRX

100.0%

+0.0pp

IONS

96.1%

-0.7pp

EXEL

95.6%

+0.1pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
MRNA	$21.30B	-7.5	-30.1%	15.5%
ROIV	$20.25B	-24.4	-18.3%	4.0%
RPRX	$19.75B	25.8	11.9%	45.6%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

39.0%

高成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

50%

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年4月29日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし